Biote reports Q2 EPS 10c, one estimate 13c

Reports Q2 revenue $48.9M, consensus $49.5M. “Consistent with our action plan to drive structural and cultural change, Biote (BTMD) initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable growth in the years ahead,” said Bret Christensen, CEO. “While many difficult actions were taken, I am pleased with the initial progress we have already achieved, which has included new leadership, an expansion of corporate talent and an upgraded sales compensation structure that I believe will enable us to enhance productivity and drive long-term success. Second quarter revenue decreased slightly year-over-year. Second quarter Adjusted EBITDA increased 19.1% year-over-year, reflecting a shift of our 2025 annual marketing event from the second to the third quarter as well as efficiency gains from the vertical integration of our 503B manufacturing facility. As we move forward, we remain focused on advancing our key strategic priorities: accelerating new providers, maximizing value from top tier clinics, and strengthening our commercial organization.”